Rigel Pharmaceuticals, Inc. (RIGL) Rigel, rigel pharmaceuticals, novel small molecule, small molecule, drug discovery, target validation, target discovery, clinical programs, clinical trial, clinical development, r406, r788, r256, r348, r548, r549, r507, immune thrombocytopenic purpura, itp, adult itp, chronic itp, immune thrombocytopenia, immune disorders, immunology, autoimmune, oncology, immuno-oncology, syk, syk kinase, spleen tyrosine kinase, syk inhibitor, inflammatory disease, autoimmune disease, acute myeloid leukemia, AML, non small cell lunch cancer, NSCLC, solid tumors, cancer, axl, axl kinase, asthma, metabolic diseases, ampk, mdm2 inhibitor, ligase, kinase inhibitor, ubiquitin ligase, jak1, jak2, jak3, janus tyrosine kinase, pkc theta, pkc inhibitors, jak inhibitors, fostamatinib, muscle wasting, ocular gvhd, jak, pkc, muscle disorders, ampk activators, astrazeneca, jak3 inhibitor, oral syk, dry eye, ocular gvhd, daiichi sankyo, TGF beta inhibitors, TGFb inhibitors, bergenbio, epithelial-mesenchymal-transition, EMT, r428, BGB324, bristol-myers squibb collaboration, bristol-myers squibb partner, IL13, IL4, tgf beta, itp phase 3, phase 3 itp, iga nephropathy, igan, igg signaling, glomerular disease, jak syk inhibitor, ophthalmic jak inhibitor, ophthalmic syk inhibitor, fostamatinib in ITP, fostamatinib itp Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with …